To retrospectively assess the rate of high-grade primary Gleason upgrading (HGPGU) to primary Gleason pattern 4 or 5 in a contemporary cohort of patients with D'Amico low-risk prostate cancer including those who fulfilled Prostate Cancer Research International Active Surveillance (PRIAS) criteria, and to develop a tool for HGPGU prediction. HGPGU is a contraindication in most active surveillance (AS) and focal therapy protocols.
Objective
To retrospectively assess the rate of high-grade primary Gleason upgrading (HGPGU) to primary Gleason pattern 4 or 5 in a contemporary cohort of patients with D'Amico low-risk prostate cancer including those who fulfilled Prostate Cancer Research International Active Surveillance (PRIAS) criteria, and to develop a tool for HGPGU prediction. HGPGU is a contraindication in most active surveillance (AS) and focal therapy protocols.
Patients and Methods
In all, 10 616 patients with localised prostate cancer were treated at a high-volume European tertiary care centre from 2010 to 2015 with radical prostatectomy. Analyses were restricted to 1 819 patients with D'Amico low-risk prostate cancer (17.1%) with prostate-specific antigen (PSA) levels of <10.0 ng/mL, cT1c-cT2a and Gleason score ≤6, and were repeated within 772 of the men (7.3%) who fulfilled the PRIAS criteria for AS (PSA level of ≤10 ng/mL, T1c-T2, Gleason score ≤6, PSA density (PSAD) of <0.2 ng/mL 2 , ≤2 positive cores). Uni-and multivariable logistic regression models were fitted, testing predictors of HGPGU. The final logistic regression model was based on the most informative variables.
Results
There was HGPGU in 88 (4.8%) patients with D'Amico lowrisk prostate cancer and in 32 (4.1%) of the subgroup who were PRIAS eligible. Multivariable analysis predicting HGPGU for the patients with D'Amico low-risk yielded three independent predictors: age, PSAD, and clinical tumour stage (P = 0.008, P = 0.005 and P = 0.021, respectively). Within the same patients, the model using all vs the most informative variables resulted in area under the curves (AUCs) of 69.2% and 68.3%, respectively. Multivariable analysis of those who were PRIAS eligible, yielded age and number of positive cores as independent predictors of HGPGU (P = 0.002 and P = 0.049, respectively; AUC 64.9%).
Introduction
Conservative management is being promoted as the ideal method of treatment for patients with newly diagnosed favourable-risk prostate cancer [1] . In those individuals, the presence of a dominant, primary Gleason 4 or 5 pattern represents an absolute contraindication to such management, based on the majority of active surveillance (AS) [2] [3] [4] [5] [6] [7] or focal therapy protocols [8] . To date, several tools have been devised to predict Gleason score upgrading to ≥7. However, none of those demonstrated sufficient accuracy to warrant everyday use in clinical practice. Specifically, several tools achieved less than or only marginally exceeded 70% accuracy [9] [10] [11] [12] . The latter threshold is considered as the minimal threshold for a model to warrant inclusion in everyday medical decision-making. Additionally, none of the existing tools focus on prediction of high-grade primary Gleason upgrading (HGPGU). Instead, all addressed any Gleason sum upgrading (GSU), starting with Gleason grade 3 + 4. Moreover, none of the existing tools are based on truly contemporary patients, diagnosed and treated from 2000 to 2012. Last but not least, series that specifically focused on AS candidates did not provide models for individualised predictions of HGPGU [13, 14] .
Based on these considerations, we decided to assess the rate of HGPGU in a contemporary cohort of men with newly diagnosed, favourable-risk prostate cancer, who are potential candidates for AS. Moreover, we decided to develop a tool capable of accurately predicting the probability of HGPGU. Our analyses not only focused on the entire cohort of patients with favourable-risk prostate cancer, but also included the subgroup of men suitable for AS according to European Randomized study of Screening for Prostate Cancer (ERSPC) Prostate Cancer Research International Active Surveillance (PRIAS) criteria [15] . Finally, we interpreted our results, that were solely based on clinical predictors, with existing alternatives to our model, such as genetic and/or biomarkers, alone or in combination with clinical variables.
Patients and Methods
A contemporary, consecutive cohort of 10 616 patients was treated at a single high-volume European tertiary care centre from January 2010 to August 2015 for clinically localised prostate cancer with either open (ORP) or robot-assisted radical prostatectomy (RARP), as previously described [16] . Preoperative evaluation of patients included the assessment of clinical stage, PSA, and prostate volume by TRUS, which were used for PSA density (PSAD) calculation. The pretreatment PSA level (AxSYM; Abbott Diagnostics, Abbott Park, IL, USA) was measured before DRE and TRUS. Clinical stage was assigned by the attending urologist, according to the 2002 TNM system. Clinical and pathological data were prospectively recorded in an institutional database. All ORP/ RARP specimens were processed and examined by dedicated uropathologists, according to a standardised procedure in accordance with the 2005 International Society of Urological Pathology (ISUP) recommendations for Gleason grade assignment, including complete embedding of the entire prostate for histological analysis [17] . Analyses were restricted to 1 819 patients (17.1%) who exclusively underwent an extended pattern 10-core initial biopsy and who harboured a histopathologically confirmed low-risk prostate cancer at initial biopsy, according to D'Amico risk classification: PSA level of <10.0 ng/mL, Gleason score of 3 + 3 and clinical stage T1c to T2a [18] . The same analyses were repeated within a subset of 772 men (7.3%) that fulfilled the PRIAS criteria for AS: PSA level of ≤10 ng/mL, PSAD of <0.2 ng/ mL 2 , clinical stage T1c or T2 and ≤2 positive biopsy cores [15] . Exclusion criteria consisted of missing clinical and pathological variables.
Descriptive statistics included frequencies and proportions for categorical variables and means, standard deviations, medians and interquartile ranges for continuously coded variables, respectively. Univariable and multivariable logistic regression models were fitted, testing potential predictors of HGPGU, defined as the presence of primary Gleason score of ≥4 at final pathology in patients with initial biopsy Gleason score of 3 + 3. With the intent of devising the most informative and parsimonious set of variables, the final logistic regression model was developed. Regression coefficients were used to estimate the univariate and multivariate predictive accuracy of individual variables, as well as their combined effect in HGPGU prediction. In the accuracy tests, a value of 100% indicates a perfect prediction, and 50% is the equivalent to the toss of a coin. As the accuracy of a model that was developed and validated on the same data set might be artificially high, we used 2 000 bootstrap resamples for internal validation of all accuracy estimates. This technique controls for overfit bias. Finally, we relied on the Akaike information criterion to remove non-informative variables from the model [19] . All tests were two-sided with a statistical significance set at P < 0.05. Analyses were performed with the statistical package for R (the R foundation for Statistical Computing, version 3.2.2).
Results
Baseline clinical and pathological characteristics of 1 819 patients with D'Amico low-risk prostate cancer are shown in Table 1 . Of these 1 819 patients, 88 (4.8%) harboured primary Gleason 4 or 5 at final pathology. These pateints represent the focus of the main analyses. Similarly, HGPGU was observed in 32 (4.1%) patients who were PRIAS eligible, who represent the focus of the subgroup analyses. After stratification according to presence or absence of HGPGU, no statistically significant differences in all tested characteristics were identified among the patients with D'Amico low-risk prostate cancer, as well as among the PRIAS eligible subgroup. Exceptions to the above consisted of a larger proportion of cT2a stage in patients with D'Amico low-risk prostate cancer with HGPGU (14.8% vs 6.8%; P = 0.008), as well as a higher prostate volume in the HGPGU PRIAS eligible subgroup (51.2 vs 49.2 mL; P = 0.04).
In univariate analyses predicting HGPGU in the group of patients with D'Amico low-risk prostate cancer, age, PSA level, dichotomised PSAD, and clinical tumour stage were significant predictors of HGPGU (all P ≤ 0.009; Table 2 ). The area-under-the-curve (AUC) values were 58.8%, 58.6% and 59.0%, respectively, for patient age, PSA level, and PSAD, and 54.0% for clinical tumour stage. All remaining variables resulted in AUC values ≤53.3%.
Similarly, within the PRIAS eligible subgroup, univariate analyses predicting HGPGU resulted in statistically significant findings for only one variable: patient age (P = 0.003). The highest AUC values were recorded for patient age (67.0%) and the number of positive biopsy cores (58.3%).
Multivariable models predicting HGPGU, fitted within the patients with D'Amico low-risk prostate cancer group, yielded three independent predictors (Table 2 ). These consisted of age, PSAD, and clinical tumour stage with P values of 0.008, 0.005, and 0.021, respectively. The remaining variables failed to reach independent predictor status. The multivariable model predicting HGPGU based on all risk variables resulted in an AUC of 69.2%, after 2 000 bootstrap resamples. Use of the Akaike information criterion resulted in the most parsimonious and informative model. It included four of the eight initial variables: age, PSAD, clinical tumour stage, and tumour laterality at biopsy. Its accuracy was estimated at 68.3%, after 2 000 bootstrap resamples.
Within the PRIAS eligible subgroup, the categorised variable PSAD was not applicable, as all patients had a PSAD of 0.2 ng/mL² according to PRIAS criteria definition and the inclusion of continuous PSAD for test purposes did not add accuracy in either the full or most parsimonious model. Multivariable models predicting HGPGU, fitted within the PRIAS eligible subgroup, only yielded age as independent predictor (P = 0.002). The remaining variables failed to reach independent predictor status. The multivariable model predicting HGPGU, based on all risk variables, resulted in an AUC of 65.3%, after 2 000 bootstrap resamples. The most parsimonious and informative model fitted within the PRIAS eligible subgroup reached similar accuracy (64.9%).
Discussion
Several AS [20] and focal therapy [8] protocols allow inclusion of patients with Gleason grades up to 3 + 4, Gleason sum six with tertiary Gleason 4/5 patterns or even Gleason grade 4 + 3 [21] . However, the presence of a dominant, primary Gleason pattern of 4 or 5 represents an absolute contraindication in most AS [2] [3] [4] [5] [6] [7] , low dose brachytherapy [22, 23] , and focal therapy selection criteria [8] . This differentiation is based on previous series reporting a statistically significant, unfavourable outcome of patients with Gleason grade 4 + 3 compared with 3 + 4 [17, 24] . Moreover, among patients with preoperative low-risk classification according to D'Amico criteria, a highly variable, but substantial rate of Gleason upgrading to Gleason grade ≥3 + 4 was reported, ranging from 34% [25, 26] to 43.5% [27] . Consequently, it is imperative to identify patients who may harbour Gleason patterns or other disease characteristics that are incompatible with AS or focal therapy. However, no contemporary tools have been developed to help identifying patients who may potentially harbour primary Gleason 4 and 5 at final pathology, despite having a biopsy Gleason grade assignment of 3 + 3. A substantially lower accuracy to predict GSU, AUC of 66.1%, was reported in a series by Capitanio et al. [10] . The latter focused on 301 patients with D'Amico low-risk prostate cancer investigated from 2001 to 2007. Taken together, these observations, including the present report, indicate that GSU and/or HGPGU are increasingly more difficult to predict. This finding results from greater homogeneity of patients in whom predictions are sought. Specifically, the initial, most historical series (Chun et al. [31] and Bud€ aus et al. [11] ) focused on all patients with prostate cancer, from all risk group strata. Eventually, subsequently investigators (Capitanio et al. [10] ) focused on highly specific patient subsets, such as patients with D'Amico low-risk prostate cancer or on even more specific patients: the PRIAS eligible subgroup. Increasing familiarity with various risk stratification schemes contributed to more selective patient inclusion and yielded very homogeneous cohorts. This in turn resulted in the relative inability of the clinical predictors to accurately discriminate between the low-and high-risk GSU and/or HGPGU. The present results substantiate this hypothesis, as evidenced by low AUC values that originate from very homogeneous patient cohorts: D'Amico low-risk prostate cancer and PRIAS candidates.
To obviate the limitations of clinical predictors, several investigators explored the ability of genetic or biomarkers to improve the predictive yield of models aimed at HGPGU predictions. For example, the novel 4KScore (OPKO lab, Nashville, USA) is a four-kallikrein panel consisting of total, free and intact PSA and kallikrein-related peptidase 2 [32] . A clinical model to predict aggressive prostate cancer (pT3 or tumour volume >0.5 mL or Gleason grade ≥4) that incorporated age, PSA, clinical stage, number of positive cores and tumour burden was tested in combination with the 4KScore [32] . After 4KScore inclusion, the predictive accuracy of the model improved from 0.72 to 0.81, in patients with low-risk prostate cancer (Gleason score ≤6, clinical stage T1c, PSA level <10 ng/mL; P < 0.001). However, despite these promising results, it is important to note that the model was tested in a relatively historical patient cohort (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) , with important differences in baseline disease characteristics relative to contemporary patients. Such differences might have favourably influenced the accuracy of the prediction model (i.e., use of sextant biopsies). Indeed, other older models that were exclusively based on clinical variables reported similar AUCs, which were mostly >70% [33] . Moreover, the model that served as the base for 4KScore testing was designed in a Dutch population, which may not be comparable to the German population of the present study. Last but not least, unlike the present study, the 4KScore study predicted outcomes not only included HGPGU, but also focused on upstaging defined as pT3 or tumour volume >0.5 mL at RP.
Other less promising commercial biomarkers have also been investigated. For example, previous series could not confirm the independent predictor status of the prostate cancer gene 3 (PCA3) urine test (PROGENSA PCA3, Hologic Gen-Probe, San Diego, USA) for prediction of primary Gleason 4 upgrading and/or T3 upstaging in multivariate analyses [34] . This finding is supported by independent series [35] . Another biomarker, the transmembrane protease, serine 2 (TMPRSS2)-E26 transformation-specific related gene (ERG) fusion, was highly specific for presence of prostate cancer in test tissue [36, 37] . On univariate analyses, TMPRSS2-ERG fusion significantly predicted GSU to ≥7 on final histopathology in patients undergoing RP (P = 0.008) [36] . However, no AUC was reported in that study. [39] .
Taken together, these findings indicate the potential ability of biomarkers to better predict HGPGU. However, validation of these biomarkers is required, using strict criteria that rely on accurate testing and report model calibrations, within welldefined contemporary external validation cohorts.
Imaging, especially multiparametric MRI may represent an alternative to biomarkers. It is increasingly used in combination for MRI/TRUS-fusion biopsy, particularly in the repeat biopsy setting [40, 41] , as well as a monitoring tool for patients under AS [42, 43] . Recent series that tested the association between preoperative MRI and final histopathological results of patients with prostate cancer that met AS criteria, but were treated with RP, showed a clear tendency for GSU in patients with suspicious MRI [43, 44] . However, similar series examining patients with prostate cancer in the context of repeat, systematic biopsy in combination with MRI/TRUS-fusion biopsy, reported limited sensitivity (53%) but increased specificity (80%) in detection of GSU [45] . The authors concluded that stable findings on MRI are associated with absence of Gleason score progression. This implies that there are tools with potential for discriminating between patients in whom a repeat biopsy might be avoided or in whom the time interval between initial and repeated biopsy could be lengthened [46] . The limitations of the present study include that it was performed in a single European centre. Previous reports demonstrated that the characteristics of patients treated at certain European institutions may not match those treated at other European or North American institutions [7, [48] [49] [50] . Second, based on the fact that patients in the present study exclusively underwent initial biopsies, very important differences in rates of upgrading might exist at repeat biopsy, which is integral to AS protocols and is often performed in time intervals of a year. Specifically, Tosoian et al. [7, 49] reported greater proportions of HGPGU, despite similar low-risk criteria. Third, our present analyses do not contain PSA isoforms/derivatives or longitudinal inputs that are required to quantify variables such as PSA doubling time or similar metrics that could add to the accuracy of our model [51, 52] . However, investigators at Johns Hopkins have not found such metrics to be of use in AS patient follow-up [52] . Similarly, other biopsy metrics such as maximum tumour involvement per core were not available in most patients and could not be included in the analyses. However, the parameters applied in our present study are typically available at any institution. Moreover, we did not perform routine transition zone biopsies. Such biopsies were not found of value, according to investigators from Johns Hopkins, who only suggest their routine use at repeat biopsy [50] . Lastly, our database does not yet contain sufficient data regarding biomarkers, genetic markers or MRI information to allow direct analyses between the contribution of standard clinical predictors and enriched models that rely on such variables. This said, investigators at Johns Hopkins did not find PCA3 values of use in predicting AS failure [52] .
In summary, we demonstrated that HGPGU is a relatively rare phenomenon in European patients with low-risk D'Amico criteria and among the PRIAS eligible subgroup. Nonetheless, missed HGPGU may have life threatening implications as such misclassification might miss the opportunity for curative treatment. Second, we demonstrated that standard clinical predictors of HGPGU are not capable of accurately quantifying HGPGU risk. Finally, existing biomarkers and imaging modalities either do not appear to have the ability required for HGPGU prediction in everyday clinical practice or warrant further validation in contemporary AS patients to corroborate the ability of these markers and imaging methods to accurately predict AS failure and disease progression.
